Last reviewed · How we verify
Oxygen + PAP therapy
Oxygen + PAP therapy is a Small molecule drug developed by VA Office of Research and Development. It is currently FDA-approved for Obstructive sleep apnea with hypoxemia, COPD with hypoxemic respiratory failure, Acute respiratory distress.
Oxygen therapy combined with positive airway pressure (PAP) delivers supplemental oxygen while maintaining continuous airway pressure to improve oxygenation and ventilation in patients with respiratory insufficiency.
Oxygen therapy combined with positive airway pressure (PAP) delivers supplemental oxygen while maintaining continuous airway pressure to improve oxygenation and ventilation in patients with respiratory insufficiency. Used for Obstructive sleep apnea, Chronic obstructive pulmonary disease (COPD), Acute respiratory failure.
At a glance
| Generic name | Oxygen + PAP therapy |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonary |
| Phase | FDA-approved |
Mechanism of action
PAP therapy (including CPAP and BiPAP) splints the airway open to prevent collapse and improve gas exchange, while supplemental oxygen increases the fraction of inspired oxygen available for absorption. Together, these modalities enhance arterial oxygen saturation and reduce the work of breathing in patients with conditions like sleep apnea, COPD, and acute respiratory failure.
Approved indications
- Obstructive sleep apnea with hypoxemia
- COPD with hypoxemic respiratory failure
- Acute respiratory distress
- Hypoventilation syndromes
Common side effects
- Nasal congestion or irritation
- Mask discomfort or skin breakdown
- Dry mouth or throat
- Claustrophobia or intolerance
- Oxygen toxicity (with prolonged high-concentration use)
Key clinical trials
- Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP (NA)
- Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (PHASE4)
- Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center (NA)
- Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases (PHASE1)
- Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment (PHASE4)
- The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) (PHASE2)
- Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT) (NA)
- Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxygen + PAP therapy CI brief — competitive landscape report
- Oxygen + PAP therapy updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about Oxygen + PAP therapy
What is Oxygen + PAP therapy?
How does Oxygen + PAP therapy work?
What is Oxygen + PAP therapy used for?
Who makes Oxygen + PAP therapy?
What development phase is Oxygen + PAP therapy in?
What are the side effects of Oxygen + PAP therapy?
Related
- Manufacturer: VA Office of Research and Development — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonary
- Indication: Drugs for Obstructive sleep apnea with hypoxemia
- Indication: Drugs for COPD with hypoxemic respiratory failure
- Indication: Drugs for Acute respiratory distress
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing